DCx Biotherapeutics
San Diego, United States· Est.
A biotech platform creating lesion‑specific multi‑modal ADCs to deliver highly selective cancer therapies.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $150M
AI Company Overview
A biotech platform creating lesion‑specific multi‑modal ADCs to deliver highly selective cancer therapies.
Oncology
Technology Platform
MuSiC™ integrates CRISPR screens, bioinformatics, and machine learning to discover lesion‑specific intracellular and cell‑surface targets, enabling multi‑modal ADCs with CLARINET™ enzyme‑triggered payloads.
Opportunities
Lesion‑specific multi‑modal ADCs can address high‑unmet‑need patient subsets and attract partnership or out‑licensing deals with large pharma seeking precision oncology assets.
Risk Factors
Technology translation risk, regulatory uncertainty for novel dual‑logic gate ADCs, and dependence on continued financing and strategic partnerships.
Competitive Landscape
DCx competes with established ADC developers such as Seagen, AstraZeneca, and Roche, but differentiates itself through lesion‑specific target selection and enzyme‑triggered payloads that aim to improve efficacy and safety.